One Wealth Capital Management LLC Acquires Shares of 5,302 Zoetis Inc. (NYSE:ZTS)

One Wealth Capital Management LLC bought a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, HoldingsChannel reports. The fund bought 5,302 shares of the company’s stock, valued at approximately $864,000.

Several other hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Zoetis during the third quarter worth about $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded down $2.60 during trading hours on Tuesday, hitting $163.30. 1,826,928 shares of the company were exchanged, compared to its average volume of 2,198,894. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The company has a market capitalization of $73.68 billion, a PE ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a fifty day simple moving average of $173.07 and a 200-day simple moving average of $180.47.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the company earned $1.36 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ZTS. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Finally, Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.